Study drug CB-103 for advanced adenoid cystic cancer
Treatments studied
Part of Cancer clinical trials.
This Phase 1/2 study tests how well CB-103 works in people with advanced, hard-to-treat adenoid cystic carcinoma that has a specific NOTCH pathway change. The study also looks at whether combining CB-103 with either lenvatinib or abemaciclib is safe and effective for different groups of patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have adenoid cystic carcinoma confirmed by pathology, and it is advanced, metastatic, or has come back and can’t be cured
- Your tumor test shows an activating NOTCH pathway mutation (a genetic change that turns the pathway on)
- You must be 18 or older, and well enough to do daily activities (ECOG 0–1)
- You can swallow study pills, and you have at least one measurable spot tumor seen on scans
- Your blood counts and organ lab tests are within required ranges (including white blood cells, hemoglobin, platelets, kidney, liver, and bilirubin)
- You can safely take the assigned oral medication plan (lenvatinib or abemaciclib), including insurance approval or support for lenvatinib if you’re in that group
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called RGT-61159 for adults with adenoid cystic carcinoma or colorectal cancer that has returned or stopped responding to treatment. The goal is to see if the drug is safe and effective in shrinking tumors.
This trial tests an experimental drug called REM-422 for people with adenoid cystic carcinoma (ACC) that has spread, come back, or cannot be removed by surgery. The study has two parts: an early part for people with advanced ACC and a later part for those with a specific genetic change (MYB biomarker) in their tumor. The goal is to see if REM-422 can slow or stop cancer growth.
This trial tests a new drug called HG146 for people with advanced adenoid cystic carcinoma that has progressed despite previous treatments. The goal is to see if HG146 can slow or stop the cancer from growing.
This trial tests whether combining the targeted drug becotatug vedotin with chemo can shrink recurrent adenoid cystic sinus tumors that can't be fully removed by surgery. It's for people whose tumors have a specific protein called EGFR.
This trial tests a drug called enfortumab vedotin for people with adenoid cystic carcinoma (ACC) that has spread or come back. The drug is given through a vein and may help shrink tumors or slow the cancer.
This Phase 2 trial studies targeted “tyrosine kinase inhibitor” pills for adenoid cystic carcinoma that has spread or cannot be cured with surgery or radiation and is growing despite prior treatment. It’s looking for whether these pills can shrink tumors or slow progression and is mainly for adults with measurable disease on recent scans.
Hear when a new Adenoid Cystic Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.